Demographics and clinical characteristics of study participants pre-cART and 3 months post-cART
| Characteristics . | Data . |
|---|---|
| Age, mean ± SD, y | 31.75 ± 8.2 |
| Race, n (%) | |
| African American/Black | 7 (58.3) |
| White | 4 (33.3) |
| Asian | 1 (8.4) |
| Sex, n (%) | |
| Male | 11 (91.6) |
| Female | 1 (8.4) |
| CD4 count, mean ± SD, cells/µL | |
| Pre-cART (n = 12) | 469 ± 234.3 |
| Post-cART (n = 10) | 510 ± 238 |
| Platelet count, mean ± SD, ×103cells/μL | |
| Pre-cART (n = 10) | 212.9 ± 65.8 |
| Post-cART (n = 10) | 221.1 ± 45.9 |
| Viral load | |
| Pre-cART (n = 12) | |
| HIV RNA log10 copies/mL, mean (range) | 3.6 (1.7-5) |
| Not reported, n (%) | 2 (16.6) |
| Post-cART (n = 10) | |
| HIV RNA log10 copies/mL, mean (range) | 2 (1.2-4.2) |
| Undetectable, n (%) | 4 (40) |
| Characteristics . | Data . |
|---|---|
| Age, mean ± SD, y | 31.75 ± 8.2 |
| Race, n (%) | |
| African American/Black | 7 (58.3) |
| White | 4 (33.3) |
| Asian | 1 (8.4) |
| Sex, n (%) | |
| Male | 11 (91.6) |
| Female | 1 (8.4) |
| CD4 count, mean ± SD, cells/µL | |
| Pre-cART (n = 12) | 469 ± 234.3 |
| Post-cART (n = 10) | 510 ± 238 |
| Platelet count, mean ± SD, ×103cells/μL | |
| Pre-cART (n = 10) | 212.9 ± 65.8 |
| Post-cART (n = 10) | 221.1 ± 45.9 |
| Viral load | |
| Pre-cART (n = 12) | |
| HIV RNA log10 copies/mL, mean (range) | 3.6 (1.7-5) |
| Not reported, n (%) | 2 (16.6) |
| Post-cART (n = 10) | |
| HIV RNA log10 copies/mL, mean (range) | 2 (1.2-4.2) |
| Undetectable, n (%) | 4 (40) |
Individuals with HIV (n = 12) were enrolled in this study, prior to any antiretroviral therapy. Individuals (n = 10) returned following 3 months of antiretroviral treatment. No individual in this study presented with opportunistic infections or other AIDS-defining illnesses at the time of enrollment.